Menu Menu

News

Featured
COVID-19 Research Pipeline

52,228

Registered/ Published

2,731

Registered

235

Published

3,673

Registered
As at 1 April 2021
FILTERED BY > Ivermectin Clear filter

Communique # 41

1 April, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE Convalescent plasma recommendation changed to 'do not use' The Taskforce Disease Modifying and Chemoprophylaxis Panel and the Guidelines Leadership Group have incorporated the results of the convalescent plasma arm of the RECOVERY Trial (published March 10) into the body of evidence underpinning the Taskforce's recommendation on the use of convalescent plasma in treating COVID-19. As a result,...
Communique

Communique # 40

18 March, 2021
WEEK IN REVIEW UPDATES TO THE LIVING GUIDELINE New recommendation for tocilizumab in children or adolescents Further to the Taskforce's recent recommendation for the conditional use of tocilizumab for adults (25...
Communique

Guidelines update, v35.1

4 March, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Tocilizumab - The references for REMAP-CAP and COVACTA (Rosas et al.) trials have...
News

Guidelines update, version 34.1

18 February, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include:   Dutasteride - preprint publication status has been removed from the summary information...
News

Communique # 38

11 February, 2021
Message from the Taskforce Chair Dear colleagues As we enter the second year of the COVID-19 pandemic it is timely to acknowledge the important role of the Taskforce’s...
Communique

Guidelines update, version 33.1

5 February, 2021
Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include: Additional study (Mohan et al.) added to the summary information for Ivermectin recommendation: We...
News

Weekly Communique # 27

15 October, 2020
WEEK IN REVIEW New PIMS-TS recommendations The Taskforce has made two new consensus recommendations for the management of children with suspected or confirmed Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2...
Communique